1. Sabril (vigabatrin) Advisory Committee Briefing Document (2009) Ovation Pharmaceuticals. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM153780.pdf
2. Kramer G, Wohlrab G (2008) Vigabatrin. In: Pellock JM, Bourgeois BFD, Dodson WE (eds) Pediatric epilepsy: diagnosis and therapy. Demos Medical Publishing, New York, pp 699–709
3. Royal College of Ophthalmologists (2008) The ocular side-effects of vigabatrin (Sabril). Information and Guidance for Screening, London
4. Sergott RC, Wheless JW, Smith MC, Westall CA, Kardon RH, Arnold A, Foroozan R, Sagar SM (2010) Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-ophthalmology 34:20–35
5. Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. BMJ 314:180–181